TKI largely displaced IFN-α in clinical practice for CML, and in recent years IFN-α has mainly been used during pregnancy or for patients with TKI intolerance [108]. Here, IFNA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.